Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
At the J. P. Morgan Healthcare Conference 2026, Novavax’s President and CEO, John C. Jacobs, reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond. From a ...
MIDDLETON, Wis.--(BUSINESS WIRE)--Imbed Biosciences (“Imbed”), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results